 |
|
|
| |
Real-World Effectiveness of Cabotegravir + Rilpivirine in Virologically Suppressed Treatment Experienced Individuals in
Europe: Data from COMBINE-2 for Cabotegravir + Rilpivirine Study
|
| |
| |
EACS 2023 oct 20
Anton Pozniak,1 Gayathri Sridhar,2 Lambert Assoumou,1 Lionel Piroth,3 Dominique Braun,4 Carl Fletcher,5 Leigh Ragone,2 Ajay Shah,6 Jean van Wyk,7 Vani Vannappagari2, on behalf of the C2C study group
1The European treatment network for HIV, hepatitis and global infectious diseases (NEAT ID), London, UK; 2ViiV Healthcare, Durham, NC, USA; 3CHU Dijon-Bourgogne, Dijon Cedex, France; 4Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland; 5 Research Organization (KC) Ltd., London, UK; 6GlaxoSmithKline, Brentford, Middlesex, UK; 7ViiV Healthcare, London, England, UK
|
| |
|
|
|
|
|
